The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients-Reference-Cited by-同舟云学术

The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients

Published:2015-10-23 Issue:7 Volume:22 Page:964-968
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Siritho Sasitorn¹,Sato Douglas K²,Kaneko Kimihiko³,Fujihara Kazuo³,Prayoonwiwat Naraporn⁴

Affiliation:

1. Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Thailand/Bumrungrad International Hospital, Thailand

2. Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan/Department of Neurology, Faculty of Medicine, University of Sao Paulo, Brazil

3. Departments of Neurology and Multiple Sclerosis Therapeutics, Tohoku University Graduate School of Medicine, Japan

4. Division of Neurology, Department of Medicine, Siriraj Hospital, Mahidol University, Thailand

Abstract

Background: Myelin oligodendrocyte glycoprotein (anti-MOG) antibody was reported in anti-aquaporin-4 (anti-AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD) patients. Objectives: To describe clinical phenotypes associated with anti-MOG. Methods: Seventy consecutive Thai patients with inflammatory idiopathic demyelinating central nervous system disorders (IIDCD) who were previously anti-AQP4 seronegative were tested for anti-MOG. Results: Anti-MOG was positive in six patients, representing 20.7% of the IIDCD anti-AQP4 seronegative patients with a non-multiple sclerosis phenotype, and most had relapses. All first presented with optic neuritis with good visual recovery after treatment. Conclusions: Anti-MOG positive patients may have manifestations that mimic NMOSD but differ in their course and prognosis from anti-AQP4 positive NMOSD.

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458515614093

Reference10 articles.

1. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

2. Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease

3. The spectrum of neuromyelitis optica

4. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system

5. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelin Oligodendrocyte Glycoprotein Optic Neuritis Presenting With Orbital Apex Syndrome;Cureus;2023-05-13

2. The Prevalence, Demographics, Clinical Features, Neuroimaging, and Inter-ethnic Differences of MOGAD in Malaysia with Global Perspectives;Multiple Sclerosis and Related Disorders;2022-11

3. What percentage of AQP4-ab-negative NMOSD patients are MOG-ab positive? A study from the Argentinean multiple sclerosis registry (RelevarEM);Multiple Sclerosis and Related Disorders;2021-04

4. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort;Frontiers in Neurology;2021-01-12

5. Differences in Clinical Features of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis in White and Asian Race;American Journal of Ophthalmology;2020-11